Application of Advances in Molecular Testing in the Clinical Management of Breast Cancer Patients


This presentation will review how molecular testing results impact the clinical care of breast cancer patients from the perspective of a medical oncologist. Topics will include options for gene expression profiling to determine adjuvant therapy in ER-positive breast cancer, predictive biomarkers in metastatic breast cancer including PIK3CA, ESR1, PD-L1, and BRCA1/2, and implications of borderline HER2 results.

Originally presented on February 10, 2020, in Park City, Utah.

Lecture Presenter

Adam L. Cohen, MD, MS

Adam L. Cohen, MD, MS

Associate Professor of Oncology
University of Utah School of Medicine

Dr. Cohen is an associate professor in the University of Utah's Division of Oncology in the Department of Medicine. He is a Huntsman Cancer Institute (HCI) investigator and a member of the Experimental Therapeutics program. He is also the vice chair of HCI PRMC. His specialties are neuro-oncology, breast oncology and gynecologic cancers.

Dr. Cohen's research focuses on clinical trials with the goal of personalizing treatment decisions for brain and breast cancer. He uses large sets of data to study gene expression patterns related to therapy response. He also helps scientists at HCI and the University of Utah translate their lab findings into clinical trials.

He has been at the University of Utah since 2009. Cohen completed a hematology/oncology fellowship at HCI and served as chief fellow. Before HCI, Dr. Cohen was chief resident in the Department of Internal Medicine at Banner Good Samaritan Medical Center in Phoenix, Arizona. He received his medical degree from Harvard Medical School. He received his undergraduate degree from Harvard College and a Master's in Mathematics from University of Chicago.


After this presentation, participants will be able to:

  • Recognize predictive and prognostic molecular markers in breast cancer
  • Choose appropriate patients for gene expression profiling of breast tumors
  • Identify the impact of the definition of tumor subtype on treatment decisions

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories